Sanofi cabinets trial of COVID-19 drug after inconclusive outcomes

PARIS:  Hopes of getting a remedy for coronavirus suffered a setback after French pharmaceutical large Sanofi introduced on Tuesday that it was halting of Phase three scientific assessments of its Kevzara drug for critical COVID-19 circumstances as that they had discovered inconclusive outcomes .

The Phase three take a look at — usually the final earlier than official approval to be used — “did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care,” it mentioned in a press release.

Sanofi mentioned neither it nor its American companion in creating the drug, Regeneron, “envisage further clinical tests of Kevzara for the treatment of Covid-19.”

Although Kevzara “did not give us the results we were hoping for, we are proud of the work done by our team,” Sanofi international analysis head Dr John Reed mentioned within the assertion.

Since the outbreak of the coronavirus pandemic late final 12 months in China, it has claimed greater than 800,000 lives and precipitated big financial harm, sparking a worldwide race to discover a vaccine and efficient remedies.

Sanofi is one in all many corporations creating a vaccine however scientists are cautious in saying that at finest, one might solely be obtainable by the top of this 12 months for preliminary use.

Related News

Back to top button